Now that biotechs are starting to get hot again,
we're all going to start hearing about NABI. NABI
is a top-tier biotech and is the 4th or 5th largest
biotech company in the U.S. It is also making a
profit. NABI trades at a huge discount compared to
its peers. With a drug pipeline that is very
strong, NABI is set to file for FDA approval for
their HBIG product by March 1997 and has other very
promising products in Phase II and Phase III
trials. In addition to the drug pipeline, NABI's
blood plasma business is booming; the CEO said in a
biotech conference call yesterday that its 1997
supply of blood plasma is "totally committed" and
that they are working on increasing their supply to
meet 1998 demand. All this bodes well for NABI and
its shareholders who may see the stock double in
1997. Please ad your comments and views on this
great company.
|
